Literature DB >> 11377532

FK 506-mediated T-cell apoptosis induction.

K Migita1, K Eguchi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11377532     DOI: 10.1016/s0041-1345(01)01994-7

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  6 in total

1.  The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms.

Authors:  Sumudra Periyasamy; Manya Warrier; Manoranjani P M Tillekeratne; Weinian Shou; Edwin R Sanchez
Journal:  Endocrinology       Date:  2007-07-05       Impact factor: 4.736

2.  Effect of immunosuppression on the human mesangial cell cycle.

Authors:  Xiaoshuang Zhou; Biruh Workeneh; Zhaoyong Hu; Rongshan Li
Journal:  Mol Med Rep       Date:  2014-11-04       Impact factor: 2.952

Review 3.  Nanotechnology as a tool to advance research and treatment of non-oncologic urogenital diseases.

Authors:  Justin Loloi; Mustufa Babar; Kelvin P Davies; Sylvia O Suadicani
Journal:  Ther Adv Urol       Date:  2022-07-26

4.  Synergistic antitumor effect of Doxorubicin and tacrolimus (FK506) on hepatocellular carcinoma cell lines.

Authors:  Francesca Capone; Eliana Guerriero; Angela Sorice; Giovanni Colonna; Gabriella Storti; Jessica Pagliuca; Giuseppe Castello; Susan Costantini
Journal:  ScientificWorldJournal       Date:  2014-02-20

Review 5.  Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction.

Authors:  Joseph J Janicki; Michael B Chancellor; Jonathan Kaufman; Michele A Gruber; David D Chancellor
Journal:  Toxins (Basel)       Date:  2016-03-18       Impact factor: 4.546

Review 6.  Intravesical liposome drug delivery and IC/BPS.

Authors:  Joseph J Janicki; Michele A Gruber; Michael B Chancellor
Journal:  Transl Androl Urol       Date:  2015-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.